1Goodman W. G. Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant,2003,18 (suppl 3 ) :2-8
2Bleyer A J, Burke SK, Dillon M, et al. A comparison of the calcium free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperpholphatemia in hemodialysis patients. Am J Kidney Dis,1999,33(4) :694-701
3Haese PCD, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate ( FosrenolTM ) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int,2003,85 (Suppl):73-78
4Slatopolsky E, Finch J, Brown A. New vitamin D analogs. Kidney Int, 2003,85 ( Suppl ):83-87
5Ukagawa MF, Kitaoka M,Tominaga Y,et al. Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. Nephrol Dial Transplant ,2003,18 (Suppl 3):31-33
5National Kidney Foundation.Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines.Bone metabolism and disease in chronic kidney disease.Am J Kidney Dis,2003,42 (suppl):S1S201
6Argiles A,Mourad G.How do we have to use the calcium in the dialysate to optimize the management of secondary hyperparathyroidism?Nephrol Dial Transplant,1998,13(suppl 3):62-64
7Argiles A,Kerr PG,Canaud B,et al.Calcium kinetics and the long-term effects of lowering dialysate calcium concentration.Kidney Int,1993,43:630-640
8Yokoyama K,Kagami S,Ohkido L,et al.The negative Ca^2+balance is involved in the stimulation of PTH secretion.Nephron,2002,92(1):86-90
9Francisco ALM.Secondary hyperparathyroidism:Review of the disease and its treatment.Clinical Therapeutics,2004,26(12):1976-1993
10Gallieni M,Cunniniello E,dmaro E,et al.Calcium,phophate,and PTH levels in the hemodialysis population:A multicenter study.J Nephrol,2002,15:165-170
